This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de Tricida, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.03 |
| 52 Week High | US$13.51 |
| 52 Week Low | US$0.025 |
| Beta | 0.063 |
| 1 Month Change | 0% |
| 3 Month Change | -17.36% |
| 1 Year Change | -99.66% |
| 3 Year Change | -99.90% |
| 5 Year Change | n/a |
| Change since IPO | -99.89% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 1T7 | DE Pharmaceuticals | Mercado DE | |
|---|---|---|---|
| 7D | 0% | 1.5% | -1.0% |
| 1Y | -99.7% | -26.5% | 2.2% |
Rentabilidad vs. Industria: 1T7 underperformed the German Pharmaceuticals industry which returned -6.1% over the past year.
Rentabilidad vs. Mercado: 1T7 underperformed the German Market which returned -6.2% over the past year.
Volatilidad de los precios
| 1T7 volatility | |
|---|---|
| 1T7 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Precio estable de las acciones: 1T7's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine 1T7's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2013 | 57 | Gerrit Klaerner | www.tricida.com |
Resumen de fundamentos de Tricida, Inc.
| Estadísticas fundamentales de 1T7 | |
|---|---|
| Capitalización bursátil | €367.97k |
| Beneficios(TTM) | -€121.31m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)0.0x
Ratio precio-beneficio (PE)¿Está 1T7 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 1T7 | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$133.91m |
| Beneficios | -US$133.91m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.31 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | -143.5% |
¿Cómo se ha desempeñado 1T7 a largo plazo?
Ver rendimiento histórico y comparativa